BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 22446615)

  • 1. JAK2 mutation-negative essential thrombocythemia in a child presenting with cerebral venous thrombosis.
    Khan AA; Kumar V; Anand I; Kumar M; Sharma P; Bhargava M
    Hematol Oncol Stem Cell Ther; 2012; 5(1):66-8. PubMed ID: 22446615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
    Allegra A; Alonci A; Penna G; D'Angelo A; Rizzotti P; Granata A; Musolino C
    Acta Haematol; 2009; 121(4):218-20. PubMed ID: 19478480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
    Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis.
    Kurosawa H; Okuya M; Matsushita T; Kubota T; Endoh K; Kuwashima S; Hagisawa S; Sato Y; Fukushima K; Sugita K; Okada Y; Park MJ; Hayashi Y; Arisaka O
    J Pediatr Hematol Oncol; 2009 Sep; 31(9):678-80. PubMed ID: 19707158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Most pediatric patients with essential thrombocythemia show hypersensitivity to erythropoietin in vitro, with rare JAK2 V617F-positive erythroid colonies.
    Veselovska J; Pospisilova D; Pekova S; Horvathova M; Solna R; Cmejlova J; Cmejla R; Belickova M; Mihal V; Stary J; Divoky V
    Leuk Res; 2008 Mar; 32(3):369-77. PubMed ID: 17719087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
    Nakatani T; Imamura T; Ishida H; Wakaizumi K; Yamamoto T; Otabe O; Ishigami T; Adachi S; Morimoto A
    Pediatr Blood Cancer; 2008 Dec; 51(6):802-5. PubMed ID: 18802948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vascular complications of essential thrombocythemia].
    Bellucci S
    Bull Acad Natl Med; 2007 Mar; 191(3):519-30; discussion 530-3. PubMed ID: 18072651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.
    Michiels JJ; Commandeur S; Hoogenboom GJ; Wegman JJ; Scholten L; van Rijssel RH; De Raeve H
    Ann Hematol; 2007 Nov; 86(11):793-800. PubMed ID: 17687555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders.
    Owens CD
    J Vasc Surg; 2010 Jul; 52(1):205-7. PubMed ID: 20434300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
    Weston H; Cowell V; Grimmett K; Saal R; Jones M; Mills T; Gill D; Marlton P; Bird R; Mollee P
    Intern Med J; 2011 May; 41(5):408-15. PubMed ID: 20681956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Essential thrombocythemia: scientific advances and current practice.
    Tefferi A
    Curr Opin Hematol; 2006 Mar; 13(2):93-8. PubMed ID: 16456375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.
    Hsiao HH; Yang MY; Liu YC; Lee CP; Yang WC; Liu TC; Chang CS; Lin SF
    Exp Hematol; 2007 Nov; 35(11):1704-7. PubMed ID: 17920754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
    Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
    Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 mutations across a spectrum of venous thrombosis cases.
    Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K
    Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients.
    Alvarez-Larrán A; Cervantes F; Bellosillo B; Giralt M; Juliá A; Hernández-Boluda JC; Bosch A; Hernández-Nieto L; Clapés V; Burgaleta C; Salvador C; Arellano-Rodrigo E; Colomer D; Besses C
    Leukemia; 2007 Jun; 21(6):1218-23. PubMed ID: 17519959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An unusual cause of cerebellar hemorrhage in a young patient: essential thrombocythemia.
    Adam R; Priglinger M; Harrington T; Gottlieb D; Krause M
    J Stroke Cerebrovasc Dis; 2014; 23(5):e373-4. PubMed ID: 24582788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.